Pacira BioSciences, Inc. (PCRX)
- Previous Close
14.33 - Open
14.56 - Bid 14.49 x 300
- Ask 14.56 x 200
- Day's Range
14.19 - 14.75 - 52 Week Range
11.16 - 35.95 - Volume
621,071 - Avg. Volume
1,441,830 - Market Cap (intraday)
670.685M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
10.85 - EPS (TTM)
1.34 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.13
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
www.pacira.com711
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PCRX
View MorePerformance Overview: PCRX
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PCRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PCRX
View MoreValuation Measures
Market Cap
670.69M
Enterprise Value
915.05M
Trailing P/E
10.85
Forward P/E
3.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.15
Price/Book (mrq)
0.76
Enterprise Value/Revenue
1.33
Enterprise Value/EBITDA
4.92
Financial Highlights
Profitability and Income Statement
Profit Margin
9.21%
Return on Assets (ttm)
3.96%
Return on Equity (ttm)
7.54%
Revenue (ttm)
690.31M
Net Income Avi to Common (ttm)
63.59M
Diluted EPS (ttm)
1.34
Balance Sheet and Cash Flow
Total Cash (mrq)
404.23M
Total Debt/Equity (mrq)
73.76%
Levered Free Cash Flow (ttm)
153.5M